Terence Flynn
Stock Analyst at Morgan Stanley
(4.37)
# 83
Out of 5,218 analysts
178
Total ratings
60.44%
Success rate
287.65%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
AbbVie | Maintains: Overweight | 231 224 | 173.5 | 29.11% | 13 | Nov 12, 2024 | |
Bristol-Myers Squibb | Maintains: Underweight | 36 39 | 55.73 | -30.02% | 10 | Nov 12, 2024 | |
Merck & Co | Maintains: Equal-Weight | 130 123 | 102.09 | 20.48% | 14 | Nov 1, 2024 | |
Johnson & Johnson | Maintains: Equal-Weight | 169 175 | 146.69 | 19.3% | 18 | Oct 16, 2024 | |
BioNTech | Upgrades: Overweight | 93 145 | 120.2 | 20.63% | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 118 | 31.19 | 278.33% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 1106 1106 | 789.07 | 40.17% | 18 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 58 | 38.47 | 50.77% | 1 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 36 | 8.43 | 327.05% | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 48 51 | 24.84 | 105.31% | 11 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 310 303 | 270.45 | 12.04% | 5 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 310 321 | 361.37 | -11.17% | 8 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 38 40 | 16.11 | 148.29% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 121 168 | 93.28 | 80.1% | 6 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 28 29 | 25.59 | 13.33% | 13 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 9 10 | 20.21 | -50.52% | 3 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 46 48 | 43.75 | 9.71% | 6 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 1 8 | 4.38 | 82.65% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 32 20 | 19.42 | 2.99% | 7 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 90 85 | 12.89 | 559.43% | 4 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 25 12 | 3.08 | 289.61% | 9 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 27 22 | 15.32 | 43.6% | 7 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 2880 | n/a | n/a | 1 | Jul 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 246 436 | 150.04 | 190.59% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 35 | n/a | n/a | 1 | Jun 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 342 | 0.37 | 92332.43% | 1 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Neutral | 54 | n/a | n/a | 3 | May 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | n/a | n/a | n/a | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 21, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Mar 13, 2017 |